The combination of neoantigen vaccines with bevacizumab and immune checkpoint inhibitors (ICIs) significantly enhances the enrichment of neoantigen-specific Mki67 T cells within tumor, thereby improving anti-tumor immune responses. This evidence concerns the gene MKI67 and neoplasm.